MONTREAL–The annual Society for Cardiovascular Angiography & Interventions (SCAI) meeting, SCAI 2026 Scientific Sessions & CAIC-ACCI Summit, will commence on Thursday, April 23, 2026, bringing thousands of researchers, clinicians, scientists, and innovators from around the world together to explore recent breakthroughs in the fields of interventional cardiology and endovascular medicine. Partnering with the Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI), the joint international conference will be held at the Palais des Congrès de Montréal in Montréal, Canada, from Thursday, April 23 to Saturday, April 25.

More than 1,900 attendees, 500 faculty, and 810 abstracts will be featured at this year’s conference, showcasing the latest clinical data, procedural guidance, and advanced expertise.

“This year’s Scientific Sessions drives home SCAI's commitment to advancing science, shaping policy, and supporting the global interventional community. Attendees will experience a rich program, strong networking, and cross-border partnerships that accelerate progress in patient care. Whether you’re seeking rigorous data, practical education, or leadership development, SCAI aims to empower clinicians at every stage of their careers,” said SCAI President Srihari S. Naidu, MD, MSCAI. “This meeting reflects the strength and momentum of our field, and our collective dedication to driving innovation that improves patients’ lives.”

The meeting also takes place at a critical moment, as nearly one million people in the U.S. and Canada die from heart disease each year, more than respiratory diseases and cancers combined. 

​“This international collaboration will showcase the next evolution of interventional cardiology. From coronary and structural to peripheral vascular to congenital, this year’s program is designed to translate innovation into real-world impact,” said Sahil A. Parikh, MD, FSCAI, Program Chair for the 2026 SCAI Scientific Sessions & CAIC-ACCI Summit. “We hope every attendee leaves primed not only with the latest evidence, but with practical strategies to improve outcomes and advance excellence across their cardiovascular teams.” 

“CAIC-ACCI and SCAI’s partnership reflects a shared commitment to elevating interventional care across the world. Through education, research, and collaboration, we are creating a more integrated approach that ensures cardiologists have the comprehensive insights needed to make confident, patient-centered decisions,” said Samer Mansour, MD, FRCPC, professor of medicine at Montreal University Hospital Center and CAIC-ACCI Committee member. “Our joint summit represents a key moment to foster cross-disciplinary dialogue and advance the standards that define high-quality cardiovascular care.” 

Key meeting themes include: 

• Coronary: As the most common heart disease, coronary heart disease presents serious risks for people across the globe as blood flow becomes restricted. Evaluating treatment of coronary heart disease can also support overall cardiovascular outcomes because it often coexists with or contributes to structural heart problems. The 2026 Scientific Sessions will showcase the following:
  • Late-breaking oral presentation: Sirolimus Eluting Balloons for Patients with Acute Coronary Syndrome – Evidence from the SELUTION DeNovo Trial
    • Date and time: Thursday, April 23; 1:35 - 1:42 PM ET
  • Late-breaking oral presentation: Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS)
    • Date and time: Thursday, April 23; 2:14 - 2:21 PM ET
  • Late-breaking oral presentation: Trial Update: Clinically Important Subgroups from STEMI D2U
    • Date and time: Thursday, April 23; 2:21 - 2:28 PM ET

• Structural: Structural heart disease is common, affecting millions of people worldwide. Hence, innovation is critical to expand treatment access, reduce risk, and improve outcomes for patients who previously had limited or no options. New data includes the following presentation:
  • Late-breaking oral presentation: AltaValve Early Feasibility Study: One-Year Outcomes with Atrial Fixation Transcatheter Mitral Valve Replacement
    • Date and time: Thursday, April 23; 1:48 - 1:55 PM ET

• Pharmacotherapy: From 2017-2020, at least 49.9% of Americans used at least one prescription drug daily, underscoring the significance of pharmacotherapy research for pain relief, infections, chronic illnesses, and more. SCAI Scientific Sessions will present pharmacotherapy data related to:
  • Late-breaking oral presentation: Lipoprotein(a) Identifies Residual Cardiovascular Risk in NIH Randomized Trials
    • Date and time: Friday, April 24; 4:21 - 4:29 PM ET
  • Newsworthy abstract: Impact of SGLT2 Inhibitors on Post-PCI Outcomes in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: A Propensity Matched Analysis
    • Date and time: Friday, April 24; 12:07 - 12:15 PM ET

• Peripheral Artery Disease (PAD): PAD affects nearly 10 million people over the age of 40 in the United States. As the leading cause of amputation, it can lead to symptoms like leg pain, cold feet, discoloration, and slow-healing wounds. This year’s meeting will feature the following PAD presentations: 
  • Late-breaking oral presentation: PROMISE III: 6-Month Clinical and Quality of Life Outcomes in CLTI Patients Treated with Transcatheter Arterialization of the Deep Veins
    • Date and time: Thursday, April 23; 2:05 - 2:13 PM ET
  • Late-breaking oral presentation: 6-Month Outcomes of the CARPOOL Study: Radial-to-Peripheral Versus Femoral Access in Lower Extremity PAD Revascularization
    • Date and time: Friday, April 24; 3:57 - 4:05 PM ET

• COVID-19: Researchers and physicians observed an increase in heart attacks, or myocardial infarctions (MI), during the first wave of global disease spread. As the world healed from the COVID-19 pandemic, experts sought to understand whether the uptick was driven by COVID-19 illness, health anxiety, or an unrelated increase in heart attacks. SCAI Scientific Sessions will release new data on those who had ST-segment Elevation Myocardial Infarction (STEMI) and COVID-19, to uncover risk factors following hospital discharge: 
  • Late-breaking oral presentation: North American COVID-19 Myocardial Infarction (NACMI) Registry: One-Year Follow-Up  
    • Date and time: Friday, April 24; 4:09-4:17 PM ET

Follow #SCAI2026 on X for breaking news and live updates straight from the conference center. Interviews with key scientists, clinicians, and members of SCAI leadership about the scientific sessions and emerging data in interventional cardiology and endovascular medicine will be available. Click here for more registration information.  

Press Contacts

Gavin Stern 

[email protected], 202-644-8561 

About SCAI 2026 Scientific Sessions

The SCAI Scientific Sessions annual meeting convenes nearly 2,000 of the world’s premier clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. With 500+ faculty and hundreds of abstracts, experts in the field work together to share the latest clinical data, procedural guidance, and advanced expertise. Highlights include live cases, featured clinical research, new SCAI clinical documents, case-based learning, and keynote speakers. For more information, visit SCAI 2026 Scientific Sessions & CAIC-ACCI Summit.

About the Society for Cardiovascular Angiography & Interventions (SCAI) 

The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 5,000 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease.  For more information, visit www.scai.org.

About Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI)

The Canadian Association of Interventional Cardiology / Association Canadienne de cardiologie d’intervention (CAIC-ACCI) is a national body representing 307 interventional cardiologists across Canada. Dedicated to advancing excellence in cardiovascular care, CAIC-ACCI plays a central role in supporting its members through high-quality educational events, fostering professional growth, and promoting innovation in clinical practice. The organization is also deeply committed to the training and development of interventional cardiology Fellows, helping to shape the next generation of specialists. For more information, visit www.caic-acci.org.